| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Pathology (Drs. Brosnan, Litwak, Neighbour, and Lyman), Neurology (Dr. Bornstein), Neuroscience (Dr. Bornstein), Microbiology and Immunology (Dr. Bloom), and Cell Biology (Dr. Bloom), Albert Einstein College of Medicine, Bronx, NY; and E.I. DuPont de Nemours & Co. (Dr. Neighbour), Glenolden Laboratories, Glenolden, PA.
Copolymer I (COP I), a nonencephalitogenic polypeptide analogous to myelin basic protein, is currently being tested for possible effectiveness in treating MS. Peripheral blood mononuclear cells from normal human donors respond blastogenically to the l-form of COP I. This response was greater than that obtained with either bovine or guinea pig myelin basic protein (GPMBP), with no specificity for a particular T-cell subset. Analyses of culture supernatants demonstrated the presence of interleukin-2 and gamma interferon. Mononuclear cells from human fetal cord blood also responded blastogenically to COP I, but the magnitude of the response did not differ from that induced by GPMBP.
Address correspondence and reprint requests to Dr. Brosnan, Albert Einstein College of Medicine, Yeshiva University, 1300 Morris Park Avenue, Building F, Room 538, Bronx, NY 10461.
Supported by USPHS grant NS 11920.
Accepted for publication April 5, 1985.
This article has been cited by other articles:
|
|
 |
|
  S Schmidt, S Balzer, C Nullen, M Schmidt, C Pohl, A von Rucker, and T Klockgether Immunomodulatory effects of glatiramer acetate on superantigen- and mitogen-induced T-cell stimulation in vitro Multiple Sclerosis, August 1, 2002; 8(4): 307 - 309. [Abstract] [PDF]
|
|
|
|
|
|
M Chen, B Gran, K Costello, K Johnson, R Martin, and S Dhib-Jalbut Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS Multiple Sclerosis, August 1, 2001; 7(4): 209 - 219. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Neuhaus, C. Farina, H. Wekerle, and R. Hohlfeld Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology, March 27, 2001; 56(6): 702 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A WINDHAGEN, S MANIAK, S MARCKMANN, A WILKENING, R-B LINDERT, F HEIDENREICH, and R BLASCZYK Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate J. Neurol. Neurosurg. Psychiatry, March 1, 2001; 70(3): 415 - 416. [Full Text]
|
|
|
|
|
|
S. Ragheb, S. Abramczyk, D. Lisak, and R. Lisak Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells Multiple Sclerosis, February 1, 2001; 7(1): 43 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 P. W. Duda, J. I. Krieger, M. C. Schmied, C. Balentine, and D. A. Hafler Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate J. Immunol., December 15, 2000; 165(12): 7300 - 7307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gran, L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin Mechanisms of immunomodulation by glatiramer acetate Neurology, December 12, 2000; 55(11): 1704 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Weiner Oral tolerance with Copolymer 1 for the treatment of multiple sclerosis PNAS, March 30, 1999; 96(7): 3333 - 3335. [Full Text] [PDF]
|
|
|
|
|
|
H. S Panitch Investigational drug therapies for treatment of multiple sclerosis Multiple Sclerosis, September 1, 1996; 2(2): 66 - 77. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
